

# Jon Snaedal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11402672/publications.pdf>

Version: 2024-02-01

40  
papers

9,036  
citations

236925

25  
h-index

265206

42  
g-index

52  
all docs

52  
docs citations

52  
times ranked

13444  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	3.4	1
2	Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 231-244.	2.6	19
3	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021, 53, 1276-1282.	21.4	430
4	Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 92.	6.2	18
5	The Power of EEG to Predict Conversion from Mild Cognitive Impairment and Subjective Cognitive Decline to Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 38-47.	1.5	25
6	Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease. <i>Brain and Behavior</i> , 2020, 10, e01630.	2.2	22
7	Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. <i>Psychiatry Research - Neuroimaging</i> , 2020, 302, 111099.	1.8	9
8	Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2019, 130, 1889-1899.	1.5	30
9	GBA and APOE $\epsilon$ 4 associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019, 9, 7013.	3.3	53
10	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	21.4	1,625
11	Does my older cancer patient have cognitive impairment?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 183-185.	1.0	10
12	Retinal oxygen metabolism in patients with mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 340-345.	2.4	27
13	Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. <i>Scientific Reports</i> , 2018, 8, 18088.	3.3	47
14	EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1359-1371.	2.6	100
15	Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 80-92.	1.5	30
16	The Association Between Midlife Physical Activity and Depressive Symptoms in Late Life: Age Gene/Environment Susceptibility's Reykjavik Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 502-507.	3.6	13
17	Retinal Oximetry Imaging in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 79-83.	2.6	65
18	Quantitative EEG Applying the Statistical Recognition Pattern Method: A Useful Tool in Dementia Diagnostic Workup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 1-12.	1.5	58

#	ARTICLE	IF	CITATIONS
19	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015, 47, 445-447.	21.4	283
20	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015, 131, 2061-2069.	1.6	145
21	The Acetylcholine Index: An Electroencephalographic Marker of Cholinergic Activity in the Living Human Brain Applied to Alzheimer's Disease and Other Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 132-142.	1.5	27
22	Variant of <i>TREM2</i> Associated with the Risk of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2013, 368, 107-116.	27.0	2,085
23	Midlife Physical Activity Preserves Lower Extremity Function in Older Adults: Age Gene/Environment Susceptibility—Reykjavik Study. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 237-242.	2.6	29
24	Diagnostic Accuracy of Statistical Pattern Recognition of Electroencephalogram Registration in Evaluation of Cognitive Impairment and Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 51-60.	1.5	48
25	Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 515.	2.2	37
26	A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. <i>Nature</i> , 2012, 488, 96-99.	27.8	1,442
27	Person-centred medicine for older people. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 379-380.	1.8	0
28	Introduction to person-centred medicine: from concepts to practice. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 330-332.	1.8	60
29	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
30	Ceruloplasmin and Iron Proteins in the Serum of Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 366-371.	1.3	33
31	Toward Person-Centered Medicine: From Disease to Patient to Person. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 304-306.	1.9	86
32	The Effect of Midlife Physical Activity on Cognitive Function Among Older Adults: AGES—Reykjavik Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2010, 65A, 1369-1374.	3.6	137
33	Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: A short review. <i>Journal of the Neurological Sciences</i> , 2010, 299, 51-54.	0.6	28
34	Introduction to conceptual explorations on person-centered medicine. <i>International Journal of Integrated Care</i> , 2010, 10, e002.	0.2	35
35	Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 55.	2.2	7
36	Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study. <i>Journal of the Neurological Sciences</i> , 2006, 241, 53-58.	0.6	34

#	ARTICLE	IF	CITATIONS
37	Ceruloplasmin, Superoxide Dismutase and Copper in Autistic Patients. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 146-148.	2.5	20
38	Copper, Ceruloplasmin and Superoxide Dismutase (SOD1) in Patients with Down's Syndrome. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 320-325.	0.0	23
39	Copper, Ceruloplasmin and Superoxide Dismutase (SOD) in Amyotrophic Lateral Sclerosis. Basic and Clinical Pharmacology and Toxicology, 2000, 87, 126-130.	0.0	18
40	Copper, Ceruloplasmin, Superoxide Dismutase and Iron Parameters in Parkinson's Disease. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 239-243.	0.0	101